



PET Radionuclides Production Cyclotron Selection and Location

*Carlos Gonzalez Lepera, Ph.D.
CYCLOTOPE and
Experimental Diagnostic Imaging,
The University of Texas MD Anderson Cancer Center
Houston, TX*

1. Cyclotron Selection
 - a. Nuclear Reactions
 - b. Production Methods
 - c. PET Radionuclides
 - d. Selection Criteria
 - e. Radionuclide Production Yield

2. Cyclotron Site
 - a. Large Vault Design
 - b. Self-Shielded Option
 - c. Facility Layout

3. PET Radionuclides Production
 - a. Gas Targets
 - b. Liquid Targets
 - c. Solid Targets



Common PET Radioisotopes

Radioisotope	Half-life	Decay (%)	β^- Endpoint (MeV)	Principal Nuclear Reactions
^{11}C	20.3 min	β^- 99.8, EC 0.2	0.961	$^{14}\text{N}(p,\alpha)^{11}\text{C}$
^{13}N	9.96 min	β^- 100	1.190	$^{16}\text{O}(p,\alpha)^{13}\text{N}$
^{15}O	122 sec	β^- 99.9, EC 0.1	1.723	$^{14}\text{N}(d,n)^{15}\text{O}$ $^{15}\text{N}(p,n)^{15}\text{O}$
^{18}F	109.8 min	β^- 96.9, EC 3.1	0.635	$^{18}\text{O}(p,n)^{18}\text{F}$ $^{20}\text{Ne}(\alpha,\alpha)^{18}\text{F}$
^{64}Cu	3.41 hr	β^- 62, EC 38	1.205	$^{60}\text{Ni}(d,n)^{64}\text{Cu}$ $^{63}\text{Ni}(p,n)^{64}\text{Cu}$
^{62}Cu (gen.)	9.73 min	β^- 97.8, EC 2.2	2.934	$^{63}\text{Cu}(p,2n)^{62}\text{Zn}(9.1\text{ hr}) \rightarrow ^{62}\text{Cu}$
^{64}Cu	12.7 hr	β^- 19, EC 41, β^+ 40	0.657	$^{64}\text{Ni}(p,n)^{64}\text{Cu}$, $^{64}\text{Zn}(n,p)^{64}\text{Cu}$
^{82}Rb (gen.)	75 sec	β^- 96, EC 4	3.35	$^{85}\text{Rb}(p,4n)^{82}\text{Sr}(25\text{ d}) \rightarrow ^{82}\text{Rb}$
^{90}Y	14.7 hr	β^- 34, EC 66	1.248, others	$^{86}\text{Sr}(p,n)^{90}\text{Y}$
^{124}I	4.15 d	β^- 25, EC 75	1.533, 2.134	$^{124}\text{Te}(p,n)^{124}\text{I}$

§ Cyclotron Selection Criteria §

Purpose	Commercial Distribution	Distribution & Research	Clinical Research	Pre-Clinical Research
Radionuclide	^{18}F	^{11}C , ^{13}N , ^{15}O , ^{18}F , solid	^{11}C , ^{13}N , ^{15}O , ^{18}F , solid	^{11}C , ^{15}O , ^{18}F
Activity	~ 10 Ci/batch	> 1 Ci/batch	~ 1 Ci/batch	< 1 Ci/batch
Particles	H^+	H^+ , D^+	H^+ , D^+	H^+
Energy	$\geq 15\text{ MeV}$	$\geq 15\text{ MeV}$	$\geq 15\text{ MeV}$	$\geq 7\text{ MeV}$

Shielding options: Self + Vault (~30 cm concrete)
Vault (~ 200 cm concrete)

Long term investment >10 years \longrightarrow Long term needs

Radionuclide Production Yields

Disintegration Rate: $D = N \cdot \lambda_A$ N : Number of atoms
(Activity) λ_A : Probability of decay
 $\lambda_A = \ln(2)/T_{1/2}$

Bateman's equation (balance) for growth of daughter radionuclide B from parent A


$$B \cdot \lambda_B = (A \cdot \lambda_A) \frac{\lambda_B}{\lambda_B - \lambda_A} (1 - e^{-(\lambda_B - \lambda_A)t})$$

A : Number of target atoms. $A \gg 1$
 λ_A : Probability of transforming target atom A into B $\lambda_A \ll 1$
The product $A \cdot \lambda_A$ remains finite.

$\lambda_A \ll \lambda_B \Rightarrow$

$$B \cdot \lambda_B = A \cdot \lambda_A (1 - e^{-\lambda_B t})$$

Probability of transforming atom A into B



$$\lambda_A = I \cdot \sum_{x_1}^{x_2} \sigma(x) \cdot dx \quad \Rightarrow \quad \lambda_A = I \cdot \int_{E_1}^{E_2} \frac{\sigma(E)}{(dE/dx)} \cdot dE$$

Radionuclide Production Yield

$$B \cdot \lambda_B = I \left(1 - e^{-\lambda_B \cdot t}\right) \cdot \frac{N_A \cdot \rho}{M} \cdot \int_{E_i}^{E_{th}} \frac{\sigma(E)}{(dE/dx)} dE$$

Yield (mCi)


(I) Beam Current (μA)

Build-up (irradiation time)


Saturation Yield (mCi/μA)

$$B \lambda_B = I \left(1 - e^{-\lambda_B t}\right) N_A \rho / M \int \sigma(E) dE / (dE/dx)$$

Irradiation Build Up




$$B \lambda_B = I \left(1 - e^{-\lambda_B t}\right) N_A \rho / M \int \sigma(E) dE / (dE/dx)$$



1 mbarn = 10⁻²⁷ cm²

$$B \lambda_B = I \left(1 - e^{-\lambda_B t}\right) N_A \rho / M \int \sigma(E) dE / (dE/dx)$$



Production Efficiency


How many protons per produced ^{18}F atom are needed?
 $^{18}\text{O}(p,n)^{18}\text{F}$

Protons Energy [MeV]	Yield* [mCi/ μA]	^{18}F at EOB [mCi]	Protons/ ^{18}F
10.5	120	950	1700
18	200	1583	1020

Irradiation conditions : 25 μA x 60 min

* Typical production yields using >95% enriched ^{18}O -Water


Ernest Orlando Lawrence and M. Stanley Livingston



Holifield Radioactive Ion Beam Facility – Oak Ridge, TN



25 MV Terminal




Building

Comparative size for electrostatic accelerator with similar final proton energy as 40 MeV cyclotron

UT Houston – Scanditronix MC40





CYCLOTRON MENU

Sizes:

Small (PET):	K(p) < 19 MeV	self-shielded option
Medium (SPECT):	K(p) < 30 MeV	vault required
Large (Therapy):	K(p) > 30 MeV	up to few hundred MeV

Flavors:

Ion	<i>Positive</i>	<i>Negative (p, d only)</i>
Ion Source	<i>Internal</i>	<i>External</i>
Magnet	<i>Conventional</i>	<i>Superconducting</i>
Plane	<i>Horizontal</i>	<i>Vertical</i>
Shielding	<i>Self</i>	<i>Vault</i>
Particles	<i>Single</i>	<i>Multiple (p,d,α,He3)</i>
Energy	<i>Fixed</i>	<i>Variable (steps-cont.)</i>

Siemens Eclipse HP

11 MeV protons
60 μA (x2) max. current


MAX. POWER: 660 W (x2)

GE PETtrace

16 MeV protons
8 MeV deuterons (option)
60 μA max. current

MAX. POWER: 960 W

GE PETtrace Self-Shielded



IBA Cyclone® 18/9 -HC

18 MeV protons
9 MeV deuterons
150 μ A max. current

MAX. POWER: 2700 W



ACS TR 19/9


19 MeV protons
9 MeV deuterons
>300 μ A current




MAX. POWER: ~ 6000 W







Production Capacity





(1 target – 2 hours)





















FDA Approved:

- $^{18}\text{F}[\text{NaF}]$
- $^{18}\text{F}[\text{FDG}]$
- ^{13}N -Ammonia
- ^{82}Rb

Potential New Tracers	Primary Application
F18-Acetate	Oncology/Cardiology
F18-Fluorodopa	Neurology -Oncology
F18-FLT	Oncology -DNA marker -Cell Proliferation
C11 - PIB	Detection Alzheimer's disease (F18)
C11 - Acetate	Heart/Prostate
C11 - Palmitate	Fatty Acid Metab - Heart
C11 - Tracers	Brain Receptors
1124 - MoAb	Oncology/Diag -Treatment
Cu-61/64 ATSM	Hypoxia
Zn62/Cu62 Generator	Heart

FDG



Fluoroacetate



Thank you